Acyl Sulfonamide NaV1.7 Inhibitors Selective Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain management lack selective inhibitors for NaV1.7 channels, which are crucial for pain perception, leading to inadequate analgesic effects and side effects due to non-selectivity over other NaV subtypes.
Innovation Solution
Development of compounds of formula I, which are selective inhibitors of NaV1.7 channels, comprising specific structural elements such as thiazolyl or thiadiazolyl groups and pharmaceutically acceptable salts, designed to target the voltage-sensitive domain of the NaV1.7 channel, thereby providing potent and selective analgesic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective NaV channel inhibitors are used for pain management, then analgesic effects are achieved, but side effects increase due to lack of selectivity over other NaV subtypes
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (thiazolyl or thiadiazolyl groups at defined positions on the benzenesulfonamide core) that confer selective affinity for NaV1.7 channel. This localized structural modification enables the inhibitor to target specifically the voltage-sensing domain of NaV1.7 while sparing other NaV subtypes, thereby achieving effective pain relief with reduced side effects
2Object-affected harmful factors
If selective NaV1.7 inhibitors are developed, then side effects are reduced, but compound complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying specific molecular parameters of the benzenesulfonamide core structure - particularly the substitution pattern (4-substituted), the nature of the nitrogen-containing aromatic ring (thiazolyl or thiadiazolyl), and the position of halogen or other substituents. These controlled parameter modifications enable fine-tuning of selectivity for NaV1.7 while maintaining a relatively simple overall molecular framework that is amenable to synthesis
Data Source
AI summary
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (I)